Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Standard 6-Month Regimen (Isoniazid, Rifampicin, Pyrazinamide, Ethambutol then Isoniazid, Rifampicin for active TB)
Treatment for Drug-susceptible tuberculosis
Typical Dosage: Isoniazid 300mg daily, Rifampicin 600mg daily, Pyrazinamide 1500-2000mg daily, Ethambutol 800-1200mg daily
Effectiveness
95%
Safety Score
58%
Clinical Trials
500
Participants
200K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
58
DangerousModerateSafe
Treatment Details
Dosage Range
Isoniazid 300mg daily, Rifampicin 600mg daily, Pyrazinamide 1500-2000mg daily, Ethambutol 800-1200mg daily
Time to Effect
2-4 weeks for clinical improvement, 2 months for sputum conversion
Treatment Duration
6 months
Evidence Quality
HIGHNumber Needed to Harm (NNH)
35(Treat 35 patients to see 1 additional serious adverse event)
Confidence Score
98%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$400
Monitoring:$1,500
Side Effect Mgmt:$300
Total Annual:$2,200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$15,000/QALY
QALYs Gained
1.5
Outcome-Based Costs
Cost per Responder
$2,316
Cost per Remission
$2,391
Standard 6-Month Regimen (Isoniazid, Rifampicin, Pyrazinamide, Ethambutol then Isoniazid, Rifampicin for active TB) Outcomes
for Drug-susceptible tuberculosis
Efficacy Outcomes
Overall Effectiveness
+95%
Response Rate
+95%
Remission Rate
+92%
Common Side Effects
Hepatotoxicity (elevated LFTs, clinical hepatitis)
+20%
Peripheral neuropathy
+20%
GI upset (nausea, vomiting, abdominal pain)
+15%
Arthralgia
+20%
Optic neuritis
+5%
Orange/red discoloration of body fluids
+100%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov